Oryzon Genomics' market value is the price at which a share of Oryzon Genomics trades on a public exchange. It measures the collective expectations of Oryzon Genomics SA investors about its performance. Oryzon Genomics is trading at 3.60 as of the 8th of February 2026. This is a 7.14% up since the beginning of the trading day. The stock's lowest day price was 3.6. With this module, you can estimate the performance of a buy and hold strategy of Oryzon Genomics SA and determine expected loss or profit from investing in Oryzon Genomics over a given investment horizon. Check out Oryzon Genomics Correlation, Oryzon Genomics Volatility and Oryzon Genomics Performance module to complement your research on Oryzon Genomics.
It's important to distinguish between Oryzon Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oryzon Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Oryzon Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Oryzon Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oryzon Genomics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oryzon Genomics.
0.00
11/10/2025
No Change 0.00
0.0
In 3 months and 1 day
02/08/2026
0.00
If you would invest 0.00 in Oryzon Genomics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Oryzon Genomics SA or generate 0.0% return on investment in Oryzon Genomics over 90 days. Oryzon Genomics is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetic... More
Oryzon Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oryzon Genomics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oryzon Genomics SA upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oryzon Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oryzon Genomics' standard deviation. In reality, there are many statistical measures that can use Oryzon Genomics historical prices to predict the future Oryzon Genomics' volatility.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Oryzon Genomics. Your research has to be compared to or analyzed against Oryzon Genomics' peers to derive any actionable benefits. When done correctly, Oryzon Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Oryzon Genomics SA.
Oryzon Genomics February 8, 2026 Technical Indicators
At this point, Oryzon Genomics is somewhat reliable. Oryzon Genomics SA maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. We have found nineteen technical indicators for Oryzon Genomics SA, which you can use to evaluate the volatility of the company. Please check Oryzon Genomics' Risk Adjusted Performance of 0.0056, variance of 1.52, and Coefficient Of Variation of 37419.7 to confirm if the risk estimate we provide is consistent with the expected return of 0.0034%. The company holds a Beta of 0.13, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oryzon Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oryzon Genomics is expected to be smaller as well. Oryzon Genomics SA right now holds a risk of 1.25%. Please check Oryzon Genomics SA variance, as well as the relationship between the kurtosis and price action indicator , to decide if Oryzon Genomics SA will be following its historical price patterns.
Auto-correlation
-0.3
Weak reverse predictability
Oryzon Genomics SA has weak reverse predictability. Overlapping area represents the amount of predictability between Oryzon Genomics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oryzon Genomics SA price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current Oryzon Genomics price fluctuation can be explain by its past prices.
Other Information on Investing in Oryzon Pink Sheet
Oryzon Genomics financial ratios help investors to determine whether Oryzon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.